Another manufacturer recalled valsartan antihypertensives. Which bundles are affected, read here.
Valsartan's Mylan Laboratories Limited will not be able to use valsartan's medication until it is released. This is "Deutsche Apotheker Zeitung" with the communication of the European Medicines Agency.
Remember: Mylan affects these medicines
The impurities with N-nitrosodietilamine (NDEA) have been found in valsartan manufacturer bundles. It is a suspect that causes cancer. According to business ads, the following products and bundles were damaged:
- Valsartan lasts 40 mg, 80 mg, 160 mg and 320 mg
28, 56 and 98 films covered tablets
PZN 09239582, 09239599, 09239607, 09239613, 09239636, 09333803 and 09333826
- Valsartan / HCT (Valsartan, Hydrochlorothiazide) Mylan 80 mg / 12.5 mg, 160 mg / 12.5 mg, 160 mg / 25 mg, 320 mg / 12.5 mg and 320 mg / 25 mg
6 and 98 films covered tablets
PZN 10054959, 10054965, 10054971, 10054988, 10054994, 10055002, 10055019, 10055025, 10055031 and 10055048)
Do not stop the therapy accidentally
The European Medicines Agency, which guarantees the safety of European medicines, indicates that the risk of patients is not immediately available. As is the case with the discovery of NDMA or NDEA, patients increase their risk after interrupting the drug. You should contact your representative or pharmacist.
Mylan did not recall many valsartan products this summer due to the potentially carcinogenicity of N-nitrosodimethylamine (NDMA). All European authorities have revealed several preparations from the market since the beginning of July. Similarly, blood pressure has been recalled by lowering drug-related drugs (Irbesartan).
Important Note: This information is not replaced by professional representation or treatment by trained and approved medical personnel. ToniOnline's content can not be used and not used for independent diagnoses or treatments.